Classical Hodgkin lymphoma · 7 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Brentuximab vedotin and Dacarbazine Variant #01 | — | R 57 699 | 21d | — | — | ~17 | ~R 976 531 indirect | — |
Brentuximab vedotin monotherapy Variant #01 | — | R 56 829 | 21d | ~25.6 mo | — | ~17 | ~R 966 097 PFS proxy · indirect | 2 |
ChlVPP/EVA Variant #01 Partial | — | R 6 976 | 28d | — | — | 6 | R 29 547 PFS proxy | 1 |
VEPEMB Variant #01 Partial | — | R 5 834 | 28d | — | — | ~6 | ~R 35 005 indirect | — |
ChlVPP Variant #01 Partial | — | R 4 717 | 28d | — | — | ~8 | ~R 37 735 indirect | — |
PVAG Variant #01 | — | R 3 638 | 21d | — | — | ~8 | ~R 29 101 indirect | — |
BEACOPP Variant #01 Partial | — | R 2 042 | 21d | — | — | ~8 | ~R 16 335 indirect | — |
7 of 7 regimens shown